Rapid Decay of Anti–SARS-CoV-2 Antibodies in Persons with Mild Covid-19

Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections

Long, Q.-X., Tang, X.-J., Shi, Q.-L., Li, Q., Deng, H.-J., Yuan, J., Hu, J.-L., Xu, W., Zhang, Y., Lv, F.-J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0965-6 · Cited by 2,686

SARS‐CoV‐2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup

Stadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Roubidoux, E. K., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 635

Disappearance of Antibodies to SARS-Associated Coronavirus after Recovery

Cao, W.-C., Liu, W., Zhang, P.-H., Zhang, F., & Richardus, J. H. (2007) · New England Journal of Medicine · doi:10.1056/nejmc070348 · Cited by 367

Living on Three Time Scales: The Dynamics of Plasma Cell and Antibody Populations Illustrated for Hepatitis A Virus

Andraud, M., Lejeune, O., Musoro, J. Z., Ogunjimi, B., Beutels, P., & Hens, N. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002418 · Cited by 75

Longitudinal Analysis of Severe Acute Respiratory Syndrome (SARS) Coronavirus-Specific Antibody in SARS Patients

Chang, S., Wang, J., Huang, L., Chen, Y., Fang, C., Sheng, W., Wang, J., Yu, C., & Yang, P. (2005) · Clinical and Vaccine Immunology · doi:10.1128/cdli.12.12.1455-1457.2005 · Cited by 32

Clinical course impacts early kinetics,magnitude, and amplitude of SARS-CoV-2 neutralizing antibodies beyond 1 year after infection

Pradenas, E., Trinité, B., Urrea, V., Marfil, S., Tarrés-Freixas, F., Ortiz, R., Rovirosa, C., Rodon, J., Vergara‐Alert, J., Segalés, J., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100523 · Cited by 29

Dominant CD8+ T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination

Taus, E., Hofmann, C., Ibarrondo, F. J., Hausner, M. A., Fulcher, J. A., Krogstad, P. A., Ferbas, K. G., Tobin, N. H., Rimoin, A. W., Aldrovandi, G. M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835830 · Cited by 31

Severe Acute Respiratory Syndrome Coronavirus 2

Marks, M., O’Hara, G. A., Houlihan, C. F., Bell, L. C. K., Heightman, M., & Hart, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-08-102723-3.00139-6 · Cited by 32

The demography and characteristics of SARS-CoV-2 seropositive residents and staff of nursing homes for older adults in the Community of Madrid: the SeroSOS study

Candel, F. J., Barreiro, P., Román, J. S., Carretero, M. D. M., Sanz, J. C., Pérez-Abeledo, M., Ramos, B., Viñuela-Prieto, J. M., Canora, J., Martínez-Peromingo, F. J., et al. (2021) · Age and Ageing · doi:10.1093/ageing/afab096 · Cited by 28

Male gender and kidney illness are associated with an increased risk of severe laboratory-confirmed coronavirus disease

Murillo‐Zamora, E., Trujillo, X., Huerta, M., Ríos‐Silva, M., & Mendoza‐Cano, O. (2020) · BMC Infectious Diseases · doi:10.1186/s12879-020-05408-6 · Cited by 29

Prospective Sero-epidemiological Evaluation of SARS-CoV-2 among Health Care Workers in a German Secondary Care Hospital

Herzberg, J., Vollmer, T., Fischer, B., Becher, H., Becker, A., Sahly, H., Honarpisheh, H., Guraya, S. Y., Strate, T. G., & Knabbe, C. (2020) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2020.10.026 · Cited by 29

Mesenchymal stem cell alongside exosomes as a novel cell-based therapy for COVID-19: A review study

Dauletova, M., Hafsan, H., Mahhengam, N., Zekiy, A. O., Ahmadi, M., & Siahmansouri, H. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108712 · Cited by 29

Perspective: diagnostic laboratories should urgently develop T cell assays for SARS-CoV-2 infection

Ameratunga, R., Woon, S., Jordan, A., Longhurst, H. J., Leung, E. Y., Steele, R. H., Lehnert, K., Snell, R. G., & Brooks, A. E. S. (2021) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1905525 · Cited by 28

Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys

Kshatri, J. S., Bhattacharya, D., Praharaj, I., Mansingh, A., Parai, D., Kanungo, S., Palo, S. K., Giri, S., Pattnaik, M., Barik, S. R., et al. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821000972 · Cited by 29

Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis

Lee, E.-J., & Oh, J. E. (2021) · Molecules and Cells · doi:10.14348/molcells.2021.0075 · Cited by 30

Determinants and Dynamics of SARS-CoV-2 Infection in a Diverse Population: 6-Month Evaluation of a Prospective Cohort Study

Horton, D. B., Barrett, E. S., Roy, J., Gennaro, M. L., Andrews, T., Greenberg, P. J., Bruiners, N., Datta, P., Ukey, R., Velusamy, S. K., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab411 · Cited by 28

Levels of SARS-CoV-2 population exposure are considerably higher than suggested by seroprevalence surveys

Chen, S., Flegg, J. A., White, L. J., & Aguas, R. J. (2021) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1009436 · Cited by 28

COVID-19: The Emerging Immunopathological Determinants for Recovery or Death

Ahmad, T., Chaudhuri, R., Joshi, M. C., Almatroudi, A., Rahmani, A. H., & Ali, S. M. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.588409 · Cited by 30

Dynamics of neutralizing antibody responses to SARS-CoV-2 in patients with COVID-19: an observational study

Xu, X. P., Nie, S., Wang, Y., Long, Q., Zhu, H., Zhang, X., Sun, J., Zeng, Q., Zhao, J., Liu, L., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00611-6 · Cited by 28

Rapidly Declining SARS-CoV-2 Antibody Titers within 4 Months after BNT162b2 Vaccination

Jo, D. H., Minn, D., Lim, J., Lee, K.-D., Kang, Y. M., Choe, K. W., & Kim, K. N. (2021) · Vaccines · doi:10.3390/vaccines9101145 · Cited by 32

Profiling Antibody Response Patterns in COVID-19: Spike S1-Reactive IgA Signature in the Evolution of SARS-CoV-2 Infection

Siracusano, G., Brombin, C., Pastori, C., Cugnata, F., Noviello, M., Tassi, E., Princi, D., Cantoni, D. M., Malnati, M., Maugeri, N., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.772239 · Cited by 29

Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History

Tarkowski, M., de Jager, W., Schiuma, M., Covizzi, A., Lai, A., Gabrieli, A., Corbellino, M., Bergna, A., Ventura, C. D., Galli, M., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793191 · Cited by 28

Prevention, treatment and potential mechanism of herbal medicine for Corona viruses: A review

Liu, Y., Zhou, Y., Jiang, C.-H., Liu, J., & Chen, D. (2022) · Bioengineered · doi:10.1080/21655979.2022.2036521 · Cited by 31

Convalescent Plasma for the Prevention and Treatment of COVID-19: A Systematic Review and Quantitative Analysis

Peng, H. T., Rhind, S. G., & Beckett, A. (2021) · JMIR Public Health and Surveillance · doi:10.2196/25500 · Cited by 29

A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens

Upreti, S., & Samant, M. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03323-w · Cited by 29

Early administration of remdesivir plus convalescent plasma therapy is effective to treat COVID-19 pneumonia in B-cell depleted patients with hematological malignancies

Magyari, F., Pinczés, L. I., Páyer, E., Farkas, K., Ujfalusi, S., Diószegi, Á., Sik, M., Simon, Z., Nagy, G. N., Hevessy, Z., et al. (2022) · Annals of Hematology · doi:10.1007/s00277-022-04924-6 · Cited by 28

Sero-surveillance for IgG to SARS-CoV-2 at antenatal care clinics in three Kenyan referral hospitals: Repeated cross-sectional surveys 2020–21

Lucinde, R. K., Mugo, D., Bottomley, C., Karani, A., Gardiner, E., Aziza, R., Gitonga, J. N., Karanja, H., Nyagwange, J., Tuju, J., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265478 · Cited by 30

Persistence of Neutralizing Antibody Response up to 1 Year After Asymptomatic or Symptomatic SARS-CoV-2 Infection

Choe, P. G., Kang, C. K., Kim, K., Yi, J., Kim, E. S., Park, S. W., Kim, N. J., Park, W. B., & Oh, M. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab339 · Cited by 27

Systematic Examination of Antigen-Specific Recall T Cell Responses to SARS-CoV-2 versus Influenza Virus Reveals a Distinct Inflammatory Profile

Law, J. C., Koh, W. H., Budylowski, P., Lin, J., Yue, F., Abe, K. T., Rathod, B., Girard, M., Li, Z., Rini, J. M., et al. (2020) · The Journal of Immunology · doi:10.4049/jimmunol.2001067 · Cited by 27

IgG Antibodies Develop to Spike but Not to the Nucleocapsid Viral Protein in Many Asymptomatic and Light COVID-19 Cases

Tutukina, M. N., Kaznadzey, A., Kireeva, M. L., & Mazo, I. A. (2021) · Viruses · doi:10.3390/v13101945 · Cited by 26

SIR economic epidemiological models with disease induced mortality

Goenka, A., Liu, L., & Nguyen, M. (2021) · Journal of Mathematical Economics · doi:10.1016/j.jmateco.2021.102476 · Cited by 26

Seroprevalence of SARS-CoV-2-Specific IgG Antibodies Among Adults Living in Connecticut: Post-Infection Prevalence (PIP) Study

Mahajan, S., Srinivasan, R., Redlich, C. A., Huston, S. K., Anastasio, K., Cashman, L., Massey, D. S., Dugan, A., Witters, D., Marlar, J., et al. (2020) · The American Journal of Medicine · doi:10.1016/j.amjmed.2020.09.024 · Cited by 27

Current COVID-19 vaccine candidates: Implications in the Saudi population

Rajah, A. T., Alshamsan, A., & Al-Jedai, A. H. (2020) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2020.10.019 · Cited by 28

Longitudinal Assessment of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019

Noh, J. Y., Kwak, J.-E., Yang, J., Hwang, S. Y., Yoon, J. G., Seong, H., Hyun, H., Lim, C. S., Yoon, S., Ryou, J., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab124 · Cited by 24

Immune response to SARS‐CoV‐2 in children: A review of the current knowledge

Filippatos, F., Tatsi, E., & Michos, A. G. (2021) · Pediatric Investigation · doi:10.1002/ped4.12283 · Cited by 26

Modeling serological testing to inform relaxation of social distancing for COVID-19 control

Kraay, A. N. M., Nelson, K., Zhao, C., Demory, D., Weitz, J. S., & Lopman, B. A. (2021) · Nature Communications · doi:10.1038/s41467-021-26774-y · Cited by 27

SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort

Finch, E., Lowe, R., Fischinger, S., Aubin, M. D. S., Siddiqui, S. M., Dayal, D., Loesche, M. A., Rhee, J., Beger, S. B., Hu, Y. D., et al. (2022) · PLoS Biology · doi:10.1371/journal.pbio.3001531 · Cited by 27

Kinetics of anti-nucleocapsid IgG response in COVID-19 immunocompetent convalescent patients

Movsisyan, M., Chopikyan, A. S., Kasparova, I., Hakobjanyan, G., Carrat, F., Sukiasyan, M., Rushanyan, M., Chalabyan, M., Shariff, S., Kantawala, B., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16402-0 · Cited by 28

Immunoglobulin deficiency as an indicator of disease severity in patients with COVID-19

Husain‐Syed, F., Vadász, I., Wilhelm, J., Walmrath, H., Seeger, W., Birk, H., Jennert, B., Dietrich, H., Herold, S., Trauth, J., et al. (2020) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00359.2020 · Cited by 26

Measles, mumps and rubella: control by vaccination.

Ja, V. D., de Boo, T., & Plantinga, A. D. (1986) · PubMed · Cited by 26

The COVID-19 second wave: A perspective to be explored

Diaz, R. S., & Vergara, T. R. C. (2020) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2020.101537 · Cited by 28

Occupational Exposure in the Lombardy Region (Italy) to SARS-CoV-2 Infection: Results from the MUSTANG–OCCUPATION–COVID-19 Study

Valle, P. D., Fabbri, M., Madotto, F., Ferrara, P., Cozzolino, P., Calabretto, E., D'Orso, M. I., Longhi, E., Polosa, R., Riva, M. A., et al. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18052567 · Cited by 24

Antibody Responses One Year after Mild SARS-CoV-2 Infection

Choe, P. G., Kim, K., Kang, C. K., Suh, H. J., Kang, E., Lee, S. Y., Kim, N. J., Yi, J., Park, W. B., & Oh, M. (2021) · Journal of Korean Medical Science · doi:10.3346/jkms.2021.36.e157 · Cited by 25

Quantifying previous SARS-CoV-2 infection through mixture modelling of antibody levels

Bottomley, C., Otiende, M., Uyoga, S. M., Gallagher, K. E., Kagucia, E. W., Etyang, A. O., Mugo, D., Gitonga, J. N., Karanja, H., Nyagwange, J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26452-z · Cited by 27

Antibody-mediated immunity to SARS-CoV-2 spike

Errico, J. M., Adams, L. J., & Fremont, D. H. (2022) · Advances in immunology · doi:10.1016/bs.ai.2022.07.001 · Cited by 22

Kinetics of SARS-CoV-2 IgM and IgG Antibodies 3 Months after COVID-19 Onset in Moroccan Patients

Assaid, N., Arich, S., Charoute, H., Akarid, K., Sadat, M. A., Maaroufi, A., Ezzikouri, S., & Sarih, M. (2022) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.22-0448 · Cited by 25

Immunoglobulins response of COVID-19 patients, COVID-19 vaccine recipients, and random individuals

Al‐Tamimi, M., Tarifi, A. A., Qaqish, A., Abbas, M. M., Albalawi, H., Abu-Raideh, J. A., Salameh, M. A., & Khasawneh, A. I. (2023) · PLoS ONE · doi:10.1371/journal.pone.0281689 · Cited by 25

Viruses That Can and Cannot Coexist With Humans and the Future of SARS-CoV-2

Furuse, Y., & Oshitani, H. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2020.583252 · Cited by 24

Suspected Recurrent SARS-CoV-2 Infections Among Residents of a Skilled Nursing Facility During a Second COVID-19 Outbreak — Kentucky, July–November 2020

Cavanaugh, A. M., Thoroughman, D. A., Miranda, H., & Spicer, K. B. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7008a3 · Cited by 25

Association between SARS-CoV-2 and exposure risks in health care workers and university employees – a cross-sectional study

Nygren, D. R., Norén, J., Marinis, Y. Z. D., Holmberg, A. H., Fraenkel, C., & Rasmussen, M. (2021) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.1892819 · Cited by 24

Heterogeneous magnitude of immunological memory to SARS‐CoV‐2 in recovered individuals

Mazzoni, A., Maggi, L., Capone, M., Vanni, A., Spinicci, M., Salvati, L., Kiros, S. T., Semeraro, R., Pengue, L., Colao, M. G., et al. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1281 · Cited by 24

SARS-CoV-2-Specific Antibody and T Cell Response Kinetics According to Symptom Severity

Kim, J. Y., Kwon, J., Bae, S., Cha, H. H., Lim, J. S., Kim, M., Chung, J.-W., Park, S. Y., Lee, M. J., Kim, B.-N., et al. (2021) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.20-1594 · Cited by 26

Low risk of reinfections and relation with serological response after recovery from the first wave of COVID-19

Peghin, M., Bouza, E., Fabris, M., Martino, M. D., Palese, A., Bontempo, G., Graziano, E., Gerussi, V., Bressan, V., Sartor, A., et al. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04335-x · Cited by 26

Immunoinformatics Analysis of SARS-CoV-2 ORF1ab Polyproteins to Identify Promiscuous and Highly Conserved T-Cell Epitopes to Formulate Vaccine for Indonesia and the World Population

Gustiananda, M., Sulistyo, B. P., Agustriawan, D., & Andarini, S. (2021) · Vaccines · doi:10.3390/vaccines9121459 · Cited by 27

SARS-CoV-2 antibody prevalence and correlates of six ethnic groups living in Amsterdam, the Netherlands: a population-based cross-sectional study, June–October 2020

Coyer, L., Boyd, A. C., Schinkel, J., Agyemang, C. O., Galenkamp, H., Koopman, A. D. M., Leenstra, T., van Charante, E. P. M., van den Born, B. H., Lok, A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-052752 · Cited by 23

Immunity and infectivity in covid-19

Johnston, C., Hughes, H. C., Lingard, S., Hailey, S., & Healy, B. (2022) · BMJ · doi:10.1136/bmj-2020-061402 · Cited by 24

The Associated Factors of SARS-CoV-2 Reinfection by Omicron Variant — Guangdong Province, China, December 2022 to January 2023

Cai, C., Guangdong Field Epidemiology Training Program, G. C., Li, Y., Hu, T., Liang, R., Wang, K., Guo, C., Li, Y., Zhang, M., & Kang, M. (2023) · China CDC Weekly · doi:10.46234/ccdcw2023.075 · Cited by 24

Mathematical Modeling of Vaccines That Prevent SARS-CoV-2 Transmission

Swan, D. A., Goyal, A., Bracis, C., Moore, M., Krantz, E. M., Brown, E. R., Ojeda, E. F. C., Reeves, D. B., Gao, F., Gilbert, P. B., et al. (2021) · Viruses · doi:10.3390/v13101921 · Cited by 25

Sustained SARS-CoV-2 nucleocapsid antibody levels in nonsevere COVID-19: a population-based study

Schaffner, A., Risch, L., Weber, M. C., Thiel, S. L., Jüngert, K., Pichler, M., Wohlwend, N., Lung, T., Ritzler, M., Hillmann, D., et al. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-1347 · Cited by 23

Towards Quantitative and Standardized Serological and Neutralization Assays for COVID-19

Tian, L., Elsheikh, E. B., Patrone, P. N., Kearsley, A. J., Gaigalas, A. K., Inwood, S., Lin‐Gibson, S., Esposito, D., & Wang, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052723 · Cited by 23

Prevalence of IgG antibodies against SARS-CoV-2 among healthcare workers in a tertiary pediatric hospital in Poland

Kasztelewicz, B., Janiszewska, K., Burzyńska, J., Szydłowska, E., Migdał, M., & Dzierżanowska‐Fangrat, K. (2021) · PLoS ONE · doi:10.1371/journal.pone.0249550 · Cited by 21

SARS-CoV-2 Antibody Testing in Health Care Workers: A Comparison of the Clinical Performance of Three Commercially Available Antibody Assays

Allen, N., Brady, M., Martín, A. I. C., Domegan, L. M., Walsh, C., Houlihan, E., Kerr, C., Doherty, L., King, J., Doheny, M., et al. (2021) · Microbiology Spectrum · doi:10.1128/spectrum.00391-21 · Cited by 24

Recent Developments in SARS-CoV-2 Neutralizing Antibody Detection Methods

Ndzouboukou, J. B., Zhang, Y., & Fan, X. (2021) · Current Medical Science · doi:10.1007/s11596-021-2470-7 · Cited by 23

Mouse models in COVID-19 research: analyzing the adaptive immune response

Clever, S., & Volz, A. (2022) · Medical Microbiology and Immunology · doi:10.1007/s00430-022-00735-8 · Cited by 26

Report 41: The 2020 SARS-CoV-2 epidemic in England: key epidemiological drivers and impact of interventions

Knock, E., Whittles, L. K., Lees, J. A., Guzmán, P., Verity, R., FitzJohn, R. G., Gaythorpe, K. A. M., Imai, N., Hinsley, W. R., Okell, L., et al. (2020) · Spiral (Imperial College London) · doi:10.25561/85146 · Cited by 24

SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development

Angius, F., Puxeddu, S., Zaimi, S., Canton, S., Nematollahzadeh, S., Pibiri, A., Delogu, I., Alvisi, G., Moi, M. L., & Manzin, A. (2024) · Vaccines · doi:10.3390/vaccines13010017 · Cited by 22

COVID-19 in a patient with end-stage renal disease on chronic in-center hemodialysis after evidence of SARS-CoV-2 IgG antibodies. Reinfection or inaccuracy of antibody testing

Mendoza, J. M., & Alcaide, M. L. (2020) · IDCases · doi:10.1016/j.idcr.2020.e00943 · Cited by 22

Determinants of IgG antibodies kinetics after severe and critical COVID‐19

Greef, J. D., Scohy, A., Zech, F., Nana, F. A., Pilette, C., Gérard, L., Pothen, L., Yıldız, H., Belkhir, L., & Yombi, J. C. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27059 · Cited by 22

Evaluation of SARS-CoV-2 IgG antibody reactivity in patients with systemic lupus erythematosus: analysis of a multi-racial and multi-ethnic cohort

Saxena, A., Guttmann, A., Masson, M., Kim, M., Haberman, R. H., Castillo, R., Scher, J. U., Deonaraine, K., Engel, A., Belmont, M. H., et al. (2021) · The Lancet Rheumatology · doi:10.1016/s2665-9913(21)00114-4 · Cited by 23

Long-Term Persistence of Anti-SARS-CoV-2 Antibodies in a Pediatric Population

Méndez-Echevarría, A. M., Sainz, T., Falces‐Romero, I., de Felipe, B., Escolano, L., Alcolea, S., Pertiñez, L., Neth, O., & Calvo, C. (2021) · Pathogens · doi:10.3390/pathogens10060700 · Cited by 23

How we secured a COVID ‐19 convalescent plasma procurement scheme in Japan

Terada, M., Kutsuna, S., Togano, T., Saito, S., Kinoshita, N., Shimanishi, Y., Suzuki, T., Miyazato, Y., Inada, M., Nakamoto, T., et al. (2021) · Transfusion · doi:10.1111/trf.16541 · Cited by 22

Outcomes of COVID-19 infection in multiple sclerosis and related conditions: One-year pandemic experience of the multicenter New York COVID-19 Neuroimmunology Consortium (NYCNIC)

Klineova, S., Harel, A., Farber, R. S., DeAngelis, T. M., Zhang, Y., Hentz, R. C., Leung, T. M., Fong, K. T., Smith, T. E., Blanck, R., et al. (2021) · Multiple Sclerosis and Related Disorders · doi:10.1016/j.msard.2021.103153 · Cited by 21

People living with HIV easily lose their immune response to SARS-CoV-2: result from a cohort of COVID-19 cases in Wuhan, China

Liu, Y., Xiao, Y., Wu, S., Marley, G., Ming, F., Wang, X., Wu, M., Feng, L., Tang, W., & Liang, K. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06723-2 · Cited by 23

COVID-19 ‘asymptomatic’ patients: an old wives’ tale

Mouliou, D. S., & Gourgoulianis, K. I. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2030224 · Cited by 23

COVID-19 Vaccine: Between Myth and Truth

Piccaluga, P. P., Guardo, A. D., Lagni, A., Lotti, V., Diani, E., Navari, M., & Gibellini, D. (2022) · Vaccines · doi:10.3390/vaccines10030349 · Cited by 22

Immune features of COVID-19 convalescent individuals revealed by a single-cell RNA sequencing

Zhao, P., Zou, J., Zhou, F., Zhu, Y., Song, Q., Yu, D., & Li, X. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2022.108767 · Cited by 21

Epidemiological assessment of SARS-CoV-2 reinfection

Almadhi, M. A., Alsayyad, A., Conroy, R. M., Atkin, S. L., AlAwadhi, A. I., Al‐Tawfiq, J. A., & AlQahtani, M. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.07.075 · Cited by 23

COVID-19 Antibodies and Outcomes among Outpatient Maintenance Hemodialysis Patients

Khatri, M., Islam, S., Dutka, P., Carson, J. A., Drakakis, J., Imbriano, L. J., Jawaid, I., Mehta, T., Miyawaki, N., Wu, E., et al. (2020) · Kidney360 · doi:10.34067/kid.0006292020 · Cited by 23

Reinfection, recurrence, or delayed presentation of COVID-19? Case series and review of the literature

Elzein, F. E., Ibrahim, A. G. A., Alshahrani, F. S., Mahrous, M., Murshid, E., Aldhehyan, T., Almutiri, G., Altowairqi, M., Ahmed, M., Alsaeed, M., et al. (2021) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2021.01.002 · Cited by 23

Bergamo and Covid-19: How the Dark Can Turn to Light

Perico, N., FAGIUOLI, S., Marco, F. D., Laghi, A., Cosentini, R., Rizzo, M., Gianatti, A., Rambaldi, A., Ruggenenti, P. L., Vecchia, C. L., et al. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.609440 · Cited by 22

Longitudinal Profiling of Antibody Response in Patients With COVID-19 in a Tertiary Care Hospital in Beijing, China

Feng, X., Yin, J., Zhang, J., Hu, Y., Ouyang, Y., Qiao, S., Zhao, H., Zhang, T., Li, X., Zhang, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.614436 · Cited by 22

Persistence assessment of SARS-CoV-2-specific IgG antibody in recovered COVID-19 individuals and its association with clinical symptoms and disease severity: A prospective longitudinal cohort study

Moradi, G., Bolbanabad, A. M., Ahmadi, S., Aghaei, A., Bahrami, F., Veysi, A., Kalmarzi, R. N., Shokri, A., Ghaderi, E., Mohsenpour, B., et al. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107893 · Cited by 22

Immune Responses to the ChAdOx1 nCoV-19 and BNT162b2 Vaccines and to Natural Coronavirus Disease 2019 Infections Over a 3-Month Period

Kim, J. Y., Lim, S. Y., Park, S., Kwon, J., Bae, S., Park, J. Y., Cha, H. H., Seo, M. H., Lee, H. J., Lee, N., et al. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab579 · Cited by 21

A potential bivalent mRNA vaccine candidate protects against both RSV and SARS-CoV-2 infections

Wu, N., Zhang, J., Shen, Y., Zhang, X., Zhou, J., Wu, Y., Li, E., Meng, X., Chuai, X., Chiu, S., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.02.011 · Cited by 22

Potential SARS-CoV-2 vaccines: Concept, progress, and challenges

Hosseini, S. A., Zahedipour, F., Mirzaei, H., & Oskuee, R. K. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107622 · Cited by 26

SARS-CoV-2 specific memory B cells frequency in recovered patient remains stable while antibodies decay over timePreprint

Vaisman‐Mentesh, A., Dror, Y., Tur‐Kaspa, R., Markovitch, D., Kournos, T., Dicker, D., & Wine, Y. (2020) · medRxiv · doi:10.1101/2020.08.23.20179796 · Cited by 20

SARS-CoV-2 Antibody Isotypes in Systemic Lupus Erythematosus Patients Prior to Vaccination: Associations With Disease Activity, Antinuclear Antibodies, and Immunomodulatory Drugs During the First Year of the Pandemic

Sjöwall, J., Azharuddin, M., Frodlund, M., Zhang, Y., Sandner, L., Dahle, C., Hinkula, J., & Sjöwall, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.724047 · Cited by 19

Reinfections in COVID-19 Patients: Impact of Virus Genetic Variability and Host Immunity

Fakhroo, A. D., Al-Khatib, H. A., Thani, A. A. A., & Yassine, H. M. (2021) · Vaccines · doi:10.3390/vaccines9101168 · Cited by 21

Indoleamine 2,3-dioxygenase 1 is essential for sustaining durable antibody responses

Lightman, S. M., Peresie, J., Carlson, L. M., Holling, G. A., Honikel, M. M., Chavel, C. A., Nemeth, M. J., Olejniczak, S. H., & Lee, K. P. (2021) · Immunity · doi:10.1016/j.immuni.2021.10.005 · Cited by 23

Semi-quantitative, high throughput analysis of SARS-CoV-2 neutralizing antibodies: Measuring the level and duration of immune response antibodies post infection/vaccination

Taylor, S. C., Hurst, B., Martiszus, I., Hausman, M. S., Sarwat, S., Schapiro, J. M., Rowell, S., & Lituev, A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.07.098 · Cited by 18

Development of SARS-CoV2 humoral response including neutralizing antibodies is not sufficient to protect patients against fatal infection

Choteau, M., Scohy, A., Messe, S., Luyckx, M., Dechamps, M., Montiel, V., Yombi, J. C., Gruson, D., Limaye, N., Michiels, T., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-06038-5 · Cited by 19

Diagnostic testing for SARS-CoV-2/COVID19

Spearman, P. W. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000972 · Cited by 21

Seroprevalence of SARS-CoV-2 Antibodies in Adults and Healthcare Workers in Southern Italy

Napolitano, F., Giuseppe, G. D., Montemurro, M. V., Molinari, A. M., Donnarumma, G., Arnese, A., Pavía, M., & Angelillo, I. F. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18094761 · Cited by 19

Antibody Response Following a Two-Dose mRNA Vaccination Regimen, in Health Care Workers of a Tertiary Hospital in Athens, Greece

Kontou, E., Ranellou, K., Zoulas, D., Bletsa, A., Rompola, E., Piperaki, E., Athanasiou, N., Ampelakiotou, K., Pratikaki, M. E., Stergiopoulou, C., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11060576 · Cited by 19

A clinicopathological description of COVID ‐19‐induced chilblains ( COVID ‐toes) correlated with a published literature review

Kolivras, A., Thompson, C. T., Pastushenko, I., Mathieu, M., Bruderer, P., de Cumptich, M. D. V., Feoli, F., Harag, S., Meiers, I., Olemans, C., et al. (2021) · Journal of Cutaneous Pathology · doi:10.1111/cup.14099 · Cited by 19

Persistence of immunity to SARS-CoV-2 over time in the ski resort Ischgl

Borena, W., Bánki, Z., Bates, K., Winner, H., Riepler, L., Rössler, A., Pipperger, L., Theurl, I., Falkensammer, B., Ulmer, H., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103534 · Cited by 18

Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions

Peluso, M. J., Donatelli, J. L., & Henrich, T. J. (2021) · Translational research · doi:10.1016/j.trsl.2021.11.006 · Cited by 18

Persistence of SARS-CoV-2-Specific Antibodies for 13 Months after Infection

Kučinskaitė-Kodzė, I., Simanavičius, M., Šimaitis, A., & Žvirblienė, A. (2021) · Viruses · doi:10.3390/v13112313 · Cited by 19

Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents

Tsang, H. W., Chua, G. T., To, K. K., Wong, J. S. C., Tu, W., Kwok, J., Wong, W. H. S., Wang, X., Zhang, Y., Duque, J. S. R., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.797919 · Cited by 20

SARS-CoV-2 reinfection prevents acute respiratory disease in Syrian hamsters but not replication in the upper respiratory tract

Hansen, F., Meade-White, K. D., Clancy, C. S., Rosenke, R., Okumura, A., Hawman, D. W., Feldmann, F., Kaza, B., Jarvis, M. A., Rosenke, K., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110515 · Cited by 16

Making COVID-19 mRNA vaccines accessible: challenges resolved

Niazi, S. K. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2089121 · Cited by 19

Single-Dilution COVID-19 Antibody Test with Qualitative and Quantitative Readouts

Bortz, R. H., Florez, C., Laudermilch, E., Wirchnianski, A. S., Lasso, G., Malonis, R. J., Georgiev, G. I., Vergnolle, O., Herrera, N. G., Morano, N. C., et al. (2021) · mSphere · doi:10.1128/msphere.00224-21 · Cited by 20

Longitudinal Serology of SARS-CoV-2-Infected Individuals in India: A Prospective Cohort Study

Thiruvengadam, R., Chattopadhyay, S., Mehdi, F., Desiraju, B. K., Chaudhuri, S., Singh, S., Bhartia, V., Kshetrapal, P., Natchu, U. C. M., Wadhwa, N., et al. (2021) · American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.21-0164 · Cited by 19

Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants

Chang, M., Ke, H., Coherd, C. D., Wang, Y., Mashima, K., Kastrunes, G. M., Huang, C., & Marasco, W. A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104025 · Cited by 20

High-throughput quantitation of SARS-CoV-2 antibodies in a single-dilution homogeneous assay

Kainulainen, M. H., Bergeron, É., Chatterjee, P., Chapman, A. P., Lee, J. S., Chida, A. S., Tang, X., Wharton, R. E., Mercer, K. B., Petway, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-91300-5 · Cited by 18

Loss of Anti–SARS-CoV-2 Antibodies in Mild Covid-19

Bölke, E., Matuschek, C., & Fischer, J. C. (2020) · New England Journal of Medicine · doi:10.1056/nejmc2027051 · Cited by 95

Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19

Harrington, W. E., Trakhimets, O., Andrade, D. V., Dambrauskas, N., Raappana, A., Jiang, Y., Houck, J., Selman, W., Yang, A., Vigdorovich, V. I., et al. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100253 · Cited by 65

Neutralizing Antibodies Against SARS-CoV-2—Important Questions, Unclear Answers

Katz, M. H. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2020.4624 · Cited by 6

Longitudinal anti-SARS-CoV-2 antibody profile and neutralization activity of a COVID-19 patient

Yin, S., Tong, X., Huang, A., Shen, H., Li, Y., Liu, Y., Wu, C., Huang, R., & Chen, Y. (2020) · Journal of Infection · doi:10.1016/j.jinf.2020.06.076 · Cited by 26

Longitudinal analysis of antibody decay in convalescent COVID-19 patients

Xia, W., Li, M., Wang, Y., Kazis, L. E., Berlo, K., Melikechi, N., & Chiklis, G. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-96171-4 · Cited by 32